| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Grant revenue | - | 57,480 | 278,628 | 109,745 |
| Research and development | 345,861 | 867,345 | 388,810 | 413,987 |
| General and administrative | 929,746 | 990,863 | 987,759 | 651,486 |
| Total operating expenses | 1,275,607 | 1,858,208 | 1,376,569 | 1,065,473 |
| Total operating loss | -1,275,607 | -1,800,728 | -1,097,941 | -955,728 |
| Interest expense | -48,022 | -51,353 | -63,661 | -58,679 |
| Research and development credit | - | 0 | - | 56 |
| Total other income (expense), net | -48,022 | - | - | - |
| Net loss | -1,323,629 | -1,852,081 | -1,161,602 | - |
| Nonoperating income (expense) | - | - | - | -58,623 |
| Net loss attributable to noncontrolling interest | -12,348 | -37,661 | -21,494 | - |
| Net loss attributable to common stockholders | -1,311,281 | -1,814,420 | -1,140,108 | -1,014,351 |
| Basic loss per common share | 0 | 0 | 0 | 0 |
| Diluted loss per common share | 0 | 0 | 0 | 0 |
| Weighted average number of common shares outstanding - basic | 420,279,879 | 420,279,879 | 420,279,879 | 419,906,732 |
| Weighted average number of common shares outstanding - diluted | 420,279,879 | 420,279,879 | 420,279,879 | 419,906,732 |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)